Tracy Simonsen
Family · Bakersfield, CANPI 1023195005
Payments from drug & device makers
Across 86 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$260
- Astellas Pharma US Inc$187
- AstraZeneca$183
- Otsuka America Pharmaceutical, Inc.$163
- Lilly USA, LLC$122
- GSK$109
- plus $730 from 17 others
What the payments were for
- Food & beverage$1,65494%
- Education$996%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $260 |
| Astellas Pharma US Inc | 6 | $187 |
| AstraZeneca(2 entities) | 10 | $183 |
| Otsuka America Pharmaceutical, Inc. | 8 | $163 |
| Lilly USA, LLC | 7 | $122 |
| GSK | 6 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Amgen | 5 | $100 |
| Novo Nordisk | 5 | $97 |
| AbbVie | 3 | $48 |
| Baxter Healthcare | 2 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Abbott | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Abiomed | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Shield Therapeutics Inc | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Merck | 1 | $19 |
How this compares
$1,753 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $84,126 |
| EliquisApixaban | 24 | $31,228 |
| JardianceEmpagliflozin | 27 | $25,351 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,354 |
| RybelsusSemaglutide | 11 | $9,185 |
| Levothyroxine Sodium | 259 | $3,656 |
| Rosuvastatin Calcium | 151 | $2,943 |
| Celecoxib | 25 | $2,109 |
| Nifedipine ErNifedipine | 71 | $1,545 |
| Atorvastatin Calcium | 183 | $1,370 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,321 |
| Olmesartan Medoxomil | 53 | $985 |
| SynthroidLevothyroxine Sodium | 16 | $975 |
| Pantoprazole Sodium | 98 | $925 |
| Omeprazole | 103 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $97 | $93,31188 claims |
| PfizerEliquis | $260 | $31,22824 claims |
| Boehringer IngelheimJardiance | $42 | $25,35127 claims |
| GSKTrelegy Ellipta | $109 | $17,35425 claims |
| AbbVieSynthroid | $48 | $97516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.
Other family in Bakersfield
- Jennifer TougasBakersfield$302K
- Ashton ChaseBakersfield$86K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.